Core Viewpoint - Several innovative drug companies, including Tianchen Biopharmaceuticals, Huazhi Biopharmaceuticals, and Shanghai Baoji Pharmaceutical, have recently submitted applications to list on the Hong Kong Stock Exchange, indicating a growing interest in the market for allergy and autoimmune disease treatments [1]. Company Overview - Tianchen Biopharmaceuticals was established in October 2020 and is focused on developing innovative drugs for allergic and autoimmune diseases. The company is headquartered in Suzhou and has undergone a transformation into a joint-stock company as of August 2025 [3]. - The major shareholders of Tianchen Biopharmaceuticals include its founders, Dr. Liu Heng and Dr. Sun Naichao, along with several investment firms, controlling a total of 44.16% of the company's equity [3]. Financial Background - The company has raised multiple rounds of financing, with a notable C round in May 2025, securing 208 million RMB and achieving a post-investment valuation of approximately 2 billion RMB [4]. - Tianchen Biopharmaceuticals has reported no revenue since its inception, with net losses of 95.78 million RMB in 2023 and 137.32 million RMB in 2024, totaling a loss of 327 million RMB over two years [24][26]. Product Pipeline - Tianchen Biopharmaceuticals is developing five drug candidates, with its core product LP-003 being a next-generation anti-IgE antibody aimed at treating allergic diseases. The company plans to submit a Biologics License Application (BLA) for LP-003 in the third quarter of 2026 [18][24]. - The global market for allergy medications has seen significant growth, with the market size expected to increase from 42.8 billion USD in 2018 to 68.8 billion USD by 2024, reflecting a compound annual growth rate (CAGR) of 8.2% [9]. Market Competition - The allergy medication market is competitive, with multiple anti-IgE antibody candidates undergoing clinical trials in China. Currently, three anti-IgE antibody drugs have been approved, and six more are in clinical stages [19][21]. - Tianchen Biopharmaceuticals faces competition from established products and other candidates in the pipeline, which may impact its market entry and growth potential [20][22].

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1][2]. Group 1: Fund Performance - As of August 25, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 0.20% and a trading volume of 1.44 billion yuan [1]. - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - The latest share volume reached 6.167 billion shares, with a total fund size of 6.196 billion yuan, reflecting an increase of 1459.76% in share volume and 1540.06% in fund size since December 31, 2024 [1]. Group 2: Liquidity and Trading Activity - Over the past 20 trading days, the ETF has accumulated a trading volume of 41.093 billion yuan, averaging 2.055 billion yuan per day [1]. - Since the beginning of the year, the ETF has recorded a total trading volume of 170.432 billion yuan over 157 trading days, with an average daily trading volume of 1.086 billion yuan [1]. Group 3: Fund Holdings - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 100.96% during this period [2]. - Major holdings in the ETF include: - Innovent Biologics (9.52% holding, 263 million yuan market value) - WuXi Biologics (9.47% holding, 258 million yuan market value) - BeiGene (8.73% holding, 238 million yuan market value) - CanSino Biologics (7.62% holding, 208 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 196 million yuan market value) [2].

Core Viewpoint - CICC maintains the earnings forecast for CSPC Pharmaceutical Group (01093) for 2025 and 2026 largely unchanged, with the current stock price corresponding to a P/E ratio of 20.5x for 2025 and 17.3x for 2026. The target price is raised by 51.2% to HKD 13.00, reflecting an upside potential of 23.7% from the current stock price [1]. Group 1 - The company's 1H25 performance is in line with expectations, reporting revenue of CNY 13.273 billion, a year-on-year decline of 18.5%, and a net profit attributable to shareholders of CNY 2.548 billion, down 15.6% [2]. - The prescription drug business continues to face pressure, with 2Q25 prescription drug revenue at CNY 4.747 billion, a year-on-year decrease of 20.7% and a quarter-on-quarter decrease of 13.7%. The company anticipates improvement in 2H25 [3]. Group 2 - The company has established eight innovative R&D platforms and is expected to continue monetizing external licensing agreements. Notable agreements include ROR1 ADC with a maximum potential milestone of USD 1.225 billion, and AZ strategic cooperation with a maximum potential milestone of USD 5.22 billion [4]. - R&D investment is increasing, with 2Q25 R&D expenses at CNY 1.38 billion, accounting for 29.1% of prescription drug revenue, which is a year-on-year increase of 6.2 percentage points. The company is making progress in clinical trials for its key product SYS6010 (EGFR ADC) [5].

Market Overview - A-shares surged on Friday, with the Shanghai Composite Index rising 1.45% to 3,825 points, marking a ten-year high[16] - The Hang Seng Index and the Hang Seng Tech Index increased by 0.93% and 2.71%, respectively, reflecting strong market sentiment[12] - U.S. stocks saw significant gains, with the Dow Jones up 1.89% to 45,631 points, marking a new high[10] Monetary Policy Insights - Fed Chair Powell's speech at Jackson Hole indicated a potential interest rate cut in September, raising market expectations for three rate cuts this year, each by 25 basis points[6] - The market is pricing in a 90% probability of a rate cut in September, leading to a decline in the U.S. dollar index by 0.9% to 97.72[28][32] - Short-term U.S. Treasury yields fell nearly 10 basis points, with the 2-year yield at 3.70% and the 10-year yield at 4.25%[32] Sector Performance - In the U.S., 10 out of 11 S&P sectors rose, with consumer discretionary leading gains at 3.18%[10] - In A-shares, the technology sector saw a significant increase of 5.6%, driven by semiconductor stocks[17] Commodity and Currency Movements - Gold prices rose by 1.1% to $3,374.4 per ounce, supported by rate cut expectations[28] - The price of crude oil increased slightly, with WTI crude at $63.66 per barrel, reflecting Powell's dovish stance[28] Individual Stock Highlights - Kingsoft Cloud reported Q2 2025 revenue of 2.349 billion yuan, a year-on-year increase of 24.2%, with AI revenue growing over 120%[9] - Walmart's Q2 revenue reached $64.3 billion, up 4.5% year-on-year, driven by e-commerce and digital expansion[9]

Macro Commentary - The speech by Powell at the Jackson Hole central bank conference was more dovish than expected, interpreted by the market as a signal for a potential rate cut in September. However, two regional Fed presidents later tempered this optimism, indicating that the decision would depend on economic data [2][4]. - Inflation in the U.S. is expected to rebound in August, with a potential impact on the unemployment rate due to a decrease in immigrant labor. If inflation rises less than the unemployment rate, a rate cut in September is likely; otherwise, it may be postponed to October [2][4]. - The Fed is anticipated to cut rates again in December and potentially two more times in the following year [2][4]. Company Analysis Bilibili (BILI US) - Bilibili reported Q2 2025 earnings with total revenue of RMB 7.34 billion, a 20% year-on-year increase, meeting expectations. Adjusted net profit reached RMB 562 million, exceeding consensus estimates by 8% due to better-than-expected control of sales expenses [5]. - For Q3 2025, revenue growth is expected to slow to 4% year-on-year, primarily due to high base pressure from mobile gaming. However, advertising and value-added services are projected to remain resilient [5]. Weishijia (856 HK) - Weishijia's H1 2025 revenue grew by 14% to HKD 45.5 billion, driven by strong demand for AI computing, with cloud revenue increasing by 68% year-on-year. Net profit rose by 36% to HKD 649 million [5]. - The target price has been raised to HKD 14.2, reflecting the increased contribution from AI-related business [5]. CSPC Pharmaceutical Group (1093 HK) - CSPC reported H1 2025 total revenue of RMB 13.3 billion, with core revenue declining by 25% year-on-year. The management expects a rebound in product sales in H2 2025, with at least 5% quarter-on-quarter growth anticipated [6][7]. - The company has completed six external licensing deals since late 2024 and expects to finalize two more significant deals in H2 2025, each exceeding USD 5 billion [7][9]. Li Ning (2331 HK) - Li Ning's revenue for H1 2025 was RMB 14.8 billion, a 3% year-on-year increase, slightly above expectations. However, net profit fell by 11% to RMB 1.74 billion, reflecting challenges in retail sales and increased discounts [11][13]. - The company maintains its FY 2025 guidance, expecting stable sales growth and high single-digit net profit margins, despite pressures from inventory and promotional costs [10][11]. Binjiang Service (3316 HK) - Binjiang Service reported a 12.2% increase in net profit for H1 2025, with total revenue up 22.7%. The basic property management segment showed strong growth, benefiting from improved collection rates and property fee increases [14][16]. - The company aims to achieve a 70% dividend payout ratio and plans to pursue inclusion in the Hong Kong Stock Connect by FY 2026 [16]. Zhaosheng Microelectronics (300782 CH) - Zhaosheng Microelectronics reported Q2 2025 revenue of RMB 948 million, a 25% quarter-on-quarter increase but a 13% year-on-year decline, indicating ongoing weak demand and competitive pressures [17]. - The company has adjusted its revenue forecasts downwards for 2025 and 2026 due to persistent pricing pressures and lower-than-expected demand [17].

Core Viewpoint - CICC maintains the earnings forecast for CSPC Pharmaceutical Group (01093) for 2025 and 2026, with a target price increase of 51.2% to HKD 13.00, indicating a potential upside of 23.7% from the current stock price [1] Financial Performance - The company's 1H25 performance is in line with expectations, reporting revenue of CNY 13.273 billion, a year-on-year decline of 18.5%, and a net profit attributable to shareholders of CNY 2.548 billion, down 15.6% [2] Business Segment Analysis - The traditional pharmaceutical business continues to face pressure, with 2Q25 revenue of CNY 4.747 billion, a year-on-year decrease of 20.7% and a quarter-on-quarter decline of 13.7%. The decline is attributed to medical insurance cost control and inventory management [3] - Specific revenue breakdown includes: - Neurology: CNY 1.847 billion (YoY -27.0%) - Oncology: CNY 0.498 billion (YoY -53.5%) - Anti-infection: CNY 0.735 billion (YoY -23.2%) - Cardiovascular: CNY 0.457 billion (YoY -10.2%) - Respiratory: CNY 0.250 billion (YoY -13.5%) - Metabolism: CNY 0.229 billion (YoY -31.3%) - Other: CNY 0.374 billion (YoY +25.1%) - Licensing revenue: CNY 0.357 billion [3] Innovation and R&D - The company has established eight innovative R&D platforms and is expected to continue monetizing external licensing agreements. Notable agreements include ROR1 ADC and irinotecan liposome, with potential milestone payments totaling up to USD 1.225 billion [4] - R&D expenditure in 2Q25 reached CNY 1.38 billion, accounting for 29.1% of traditional pharmaceutical revenue, indicating a year-on-year increase of 6.2 percentage points. The company anticipates continued innovation output [5] - The clinical progress of the key product SYS6010 (EGFR ADC) is on track, with multiple clinical trials ongoing and a BLA expected in 2026 [5]

Summary of CSPC Pharma Earnings Review and Industry Insights Company Overview - **Company**: CSPC Pharma (1093.HK) - **Market Cap**: HK$121.1 billion / $15.5 billion - **Industry**: China Pharma, Biotech & Medtech Key Financial Highlights - **2Q Revenue**: Rmb 6.3 billion, down 14% year-over-year (y/y) - **Finished Drug Sales**: Rmb 4.4 billion, down 27% y/y, below expectations (GSe Rmb 5.4 billion) [1] - **CNS Drug Sales**: Declined by 27% y/y due to stricter regulatory monitoring, particularly affecting capsule sales [1] - **Oncology Sales**: Decreased by 54% y/y, impacted by value-based pricing (VBP) for Duomeisu / Jinyouli [1] - **Earnings**: Rmb 1.1 billion, down 24% y/y or 46% y/y excluding business development (BD) [1] - **R&D Expenses**: Rmb 1.4 billion, up 1% y/y; SG&A savings of 26% y/y partially offset the earnings decline [1] Management Guidance - **Sales Growth Resumption**: Expected in 2H25, with finished drug sales projected to grow by over 5% half-on-half (h/h) [1] - **Collaboration Income**: Potential for higher collaboration income for dividend payouts [1] Business Development (BD) Insights - **BD Progress**: Company is on track with three major BD deals expected in 2025, with one already delivered (platform collaboration with AZ) [3] - **SYS6010 (EGFR ADC)**: Smooth overseas development progress, with FDA approval for including China patients in trials [3][7] Metabolism Franchise Opportunities - **Licensing Deals**: Recent licensing-out deal of oral GLP-1 to Madrigal highlights potential deal-making opportunities [2] - **Pipeline Assets**: Includes oral small molecules for weight loss and muscle enhancement, monthly-dose formulations, and siRNA drugs [2] Earnings Estimates and Price Target - **Revised Earnings Estimates**: Decreased by 5.1% for 2025, 1.8% for 2026, and 9.9% for 2027 to reflect lower expectations on finished drug sales [8] - **12-Month Price Target**: Increased to HK$11.28 from HK$10.55, indicating a potential upside of 7.4% from the current price of HK$10.51 [10] Valuation Methodology - **SOTP Valuation**: - DCF-based valuation for NBP: HK$7.2 billion - New product wave: HK$69.3 billion - Legacy portfolio and generics: HK$37.0 billion - API business: HK$4.0 billion [9] Risks and Considerations - **Key Downside Risks**: - Earlier-than-expected VBP for NBP - Slower-than-expected ramp-up of new products - Failure of major R&D projects - Greater-than-expected price cut impacts on generic drug sales [9] Conclusion CSPC Pharma is navigating a challenging environment with declining sales in key segments but is positioned for potential recovery in the latter half of 2025. The company’s focus on business development and innovative product pipelines may provide avenues for growth despite current headwinds.

Core Viewpoint - The company's 1H25 performance is in line with expectations, showing a decline in revenue and net profit compared to the previous year, but there are signs of potential improvement in the second half of the year [1] Financial Performance - 1H25 revenue was 13.273 billion yuan, a year-on-year decrease of 18.5% [1] - Net profit attributable to shareholders was 2.548 billion yuan, down 15.6% year-on-year, while adjusted net profit was 2.320 billion yuan, down 27.9% year-on-year [1] - In 2Q25, the revenue from the pharmaceutical business was 4.747 billion yuan, a year-on-year decline of 20.7% and a quarter-on-quarter decline of 13.7% [1] Business Segments - Revenue from the neurology segment was 1.847 billion yuan, down 27.0% year-on-year, attributed to medical insurance cost control and inventory management [1] - Oncology revenue was 0.498 billion yuan, down 53.5% year-on-year, while anti-infection revenue was 0.735 billion yuan, down 23.2% year-on-year [1] - Cardiovascular revenue was 0.457 billion yuan, down 10.2% year-on-year, and respiratory revenue was 0.250 billion yuan, down 13.5% year-on-year [1] - Digestive metabolism revenue was 0.229 billion yuan, down 31.3% year-on-year, while other fields generated 0.374 billion yuan, up 25.1% year-on-year [1] R&D and Innovation - The company has established eight innovative R&D platforms and is expected to continue monetizing external authorizations [2] - As of now, the company has completed several significant external authorizations with potential milestone payments totaling up to 1.225 billion USD [2] - R&D expenses in 2Q25 were 1.380 billion yuan, accounting for 29.1% of pharmaceutical revenue, indicating a year-on-year increase of 6.2 percentage points [3] - The company's key product, SYS6010 (EGFR ADC), has entered Phase III clinical trials, with expectations for a BLA in 2026 [3] Profit Forecast and Valuation - The profit forecast for 2025 and 2026 remains largely unchanged, with the current stock price corresponding to a P/E ratio of 20.5x for 2025 and 17.3x for 2026 [3] - The target price has been raised by 51.2% to 13.00 HKD, reflecting a potential upside of 23.7% from the current stock price [3]

Summary of CSPC Pharmaceutical Group Conference Call Company Overview - **Company**: CSPC Pharmaceutical Group (1093.HK) - **Industry**: China Healthcare - **Current Stock Price**: HK$10.51 (as of August 22, 2025) - **Market Capitalization**: HK$125,653 million - **Price Target**: HK$9.60, indicating a downside of 9% from the current price [6][8] Key Financial Highlights - **2Q Revenue**: Decreased by 14% YoY, with finished drug sales down 27% YoY and 8% QoQ, which was 15% below estimates [8] - **Gross Profit Margin (GPM)**: Declined by 6.7 percentage points [8] - **Operating Expenses Ratio**: Increased by 8.7 percentage points YoY [8] - **Underlying Profit**: Fell by 39% YoY and 36% QoQ in 2Q; without business development (BD) income, the decline would have been 59% YoY and 24% QoQ [8] - **Fiscal Year Ending**: Expected EPS for 2025 is Rmb0.45, with revenue projected at Rmb29,036 million [6] Growth and Strategic Initiatives - **Revised Guidance**: CSPC recalibrated its target to achieve 5% half-on-half growth in 2H25, anticipating growth acceleration from 2026 [8] - **Sales Target for Mingfule**: On track to reach Rmb1 billion in sales in 2025 [2] - **Business Development (BD) Strategy**: Aims to complete two more BD deals, each exceeding US$5 billion by year-end 2025 [8] - **Focus on Retail Channels**: Plans to strengthen out-of-pocket retail channels to sustain Rmb2 billion in sales post-patent expiry [2] Clinical and Product Development - **EGFR ADC Updates**: Global Phase 3 trials for 3L+ EGFRm NSCLC and 2L+ EGFRwt NSCLC are set to begin in 2H25, with conditional approval based on Overall Response Rate (ORR) [3] - **Competitive Positioning**: Early data in China shows competitive Progression-Free Survival (PFS) and Overall Survival (OS) trends in 2L EGFRwt NSCLC compared to TROP2 ADCs [3] Technology and Pipeline - **Diverse Technology Platforms**: CSPC is nurturing eight technology platforms to support BD candidates across various therapeutic areas [4] - **Metabolic Portfolio**: Includes monthly-dosing semaglutide (Phase 1), GLP-1/GIP, and other innovative therapies [9] Risks and Challenges - **Market Risks**: Stricter reimbursement controls and Value-Based Pricing (VBP) headwinds are impacting legacy drug sales [8] - **Potential Downside Risks**: Include pipeline failures, rising operating costs, and further government price cuts [14] Analyst Ratings and Market Sentiment - **Stock Rating**: Overweight, indicating a positive outlook compared to the industry average [6] - **Industry View**: Attractive, suggesting favorable conditions for growth in the China healthcare sector [6] Conclusion CSPC Pharmaceutical Group is navigating a challenging market environment with a focus on strategic growth through business development and innovative product pipelines. The company is positioned for potential recovery and growth in the coming years, despite current financial setbacks and market pressures.

Investment Rating - The report maintains an investment rating of "Outperform" [5] Core Insights - The new drug sector has shown significant price movements, with notable gains from companies such as Beihai Kangcheng (+35.52%) and Jiahua Biological (+24.66%) during the week of August 18 to August 22, 2025 [1][16] - Upcoming academic conferences, including WCLC and ESMO, are expected to be key catalysts for the innovative drug sector, with numerous data disclosures anticipated from domestic companies [2][3][20] Summary by Sections Weekly New Drug Market Review - The new drug sector experienced substantial fluctuations, with the top five gainers being Beihai Kangcheng (+35.52%), Jiahua Biological (+24.66%), and others, while the top five losers included Geely Pharmaceutical (-16.29%) and Weichip Bio (-10.40%) [1][16] Recommended Stocks - The report suggests focusing on several potential catalysts, including overseas licensing opportunities for differentiated GLP-1 assets and upgraded PD-1 products, as well as drugs likely to benefit from medical insurance negotiations and innovative drug directories [2][20] Key Industry Analysis - Academic conferences are highlighted as crucial catalysts for the innovative drug sector, with WCLC and ESMO being particularly significant for Chinese pharmaceutical companies [20][21] New Drug Approval and Acceptance Status - No new drug approvals were reported for the week, but five new drug applications were accepted, including those from Janssen and AstraZeneca [27][28] Clinical Application Approval and Acceptance Status - A total of 47 new drug clinical applications were approved, and 28 new drug clinical applications were accepted during the week [29][30]